Stock comparison
Cytek Biosciences
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CTKB
Cytek Biosciences
Market cap
$517.86M
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CTKB | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 65C | GMAB |
| Benjamin Graham | 35D | 64C | GMAB |
| Philip Fisher | 30F | 48D | GMAB |
| Peter Lynch | 22F | 25F | GMAB |
| Joel Greenblatt | 0F | 76B | GMAB |
| Charlie Munger | 21F | 68C | GMAB |
| Terry Smith | 23F | 71C | GMAB |
Side-by-side metrics
| Metric | CTKB | GMAB |
|---|---|---|
| Market cap | $517.86M | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | -11.42% | 43.78% |
| Gross margin | 51.7% | 93.88% |
| Net margin | -36.25% | 18.23% |
| Revenue CAGR 5y | 12.02% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTKB leads on
- EV/EBIT-vs 12.0x+198%
- P/E (TTM)-vs 6.2x+188%
- Revenue CAGR 5y12.02%vs -18.45%+165%
GMAB leads on
- Net margin18.23%vs -36.25%+150%
- ROIC (TTM)43.78%vs -11.42%+126%
- Market cap$16.5Bvs $517.86M+97%
- Gross margin93.88%vs 51.7%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.